Solid Biosciences (SLDB) News Today

Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) was the recipient of a large drop in short interest during the month of July. As of July 15th, there was short interest totalling 1,660,000 shares, a drop of 45.6% from the June 30th total of 3,050,000 shares. Based on an average trading volume of 451,600 shares, the short-interest ratio is presently 3.7 days. Currently, 5.2% of the company's shares are short sold.

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Stock analysts at Leerink Partnrs cut their Q2 2024 earnings per share estimates for Solid Biosciences in a research report issued to clients and investors on Monday, July 15th. Leerink Partnrs analyst J. Schwartz now anticipates that the compa

JPMorgan Chase & Co. raised shares of Solid Biosciences from a "neutral" rating to an "overweight" rating and raised their price objective for the stock from $10.00 to $15.00 in a research note on Monday.

Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) saw a significant growth in short interest in the month of June. As of June 30th, there was short interest totalling 3,050,000 shares, a growth of 237.4% from the June 15th total of 904,100 shares. Currently, 9.6% of the company's stock are sold short. Based on an average daily volume of 393,400 shares, the days-to-cover ratio is presently 7.8 days.

Shares of Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) have been assigned a consensus rating of "Buy" from the nine analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, seven have given a buy reco

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Leerink Partnrs upped their Q2 2024 EPS estimates for Solid Biosciences in a note issued to investors on Monday, June 24th. Leerink Partnrs analyst J. Schwartz now anticipates that the company will post earnings of ($0.55) per share for the qua

Leerink Partnrs upgraded Solid Biosciences from a "hold" rating to a "strong-buy" rating in a report on Monday.

SVB Leerink upgraded Solid Biosciences from a "market perform" rating to an "outperform" rating and set a $12.00 target price for the company in a research report on Monday.

Piper Sandler reaffirmed an "overweight" rating and issued a $20.00 price target on shares of Solid Biosciences in a report on Friday.

Shares of Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seven analysts that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and six have assigned a b

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Cantor Fitzgerald lifted their FY2024 EPS estimates for Solid Biosciences in a research report issued to clients and investors on Wednesday, May 29th. Cantor Fitzgerald analyst C. Duncan now anticipates that the company will earn ($2.58) per sh

JPMorgan Chase & Co. dropped their target price on shares of Solid Biosciences from $12.00 to $10.00 and set a "neutral" rating on the stock in a research report on Friday.

Piper Sandler assumed coverage on Solid Biosciences in a research report on Friday. They set an "overweight" rating and a $20.00 target price for the company.

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Equities research analysts at HC Wainwright decreased their Q2 2024 earnings per share (EPS) estimates for Solid Biosciences in a research report issued to clients and investors on Monday, May 20th. HC Wainwright analyst A. He now forecasts tha

HC Wainwright restated a "buy" rating and set a $16.00 target price on shares of Solid Biosciences in a research report on Monday.

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Investment analysts at William Blair raised their Q3 2024 earnings per share estimates for shares of Solid Biosciences in a research report issued to clients and investors on Wednesday, May 15th. William Blair analyst T. Lugo now forecasts that

Shares of Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) have been assigned an average rating of "Buy" from the six research firms that are currently covering the stock, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month price objectiv

Barclays decreased their target price on shares of Solid Biosciences from $21.00 to $18.00 and set an "overweight" rating on the stock in a research note on Thursday.

Solid Biosciences Inc. (NASDAQ:SLDB - Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 920,900 shares, a growth of 49.8% from the March 15th total of 614,900 shares. Approximately 3.1% of the company's stock are short sold. Based on an average daily trading volume, of 362,300 shares, the days-to-cover ratio is presently 2.5 days.

William Blair restated an "outperform" rating on shares of Solid Biosciences in a research report on Thursday.

Solid Biosciences (NASDAQ:SLDB) Sets New 1-Year High at $14.99

Barclays raised their target price on Solid Biosciences from $8.00 to $21.00 and gave the company an "overweight" rating in a report on Monday.

HC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of Solid Biosciences in a research note on Thursday.

Citigroup started coverage on Solid Biosciences in a research note on Friday. They set a "buy" rating and a $16.00 price objective on the stock.

Piper Sandler upgraded Solid Biosciences from a "neutral" rating to an "overweight" rating and raised their target price for the company from $8.00 to $20.00 in a research report on Thursday.